詳細(xì)介紹
DOTA-RGD-4C,DOTA偶聯(lián)RGD-4C多肽
名稱:DOTA-RGD-4C,DOTA偶聯(lián)RGD-4C
RGD-4C 優(yōu)先結(jié)合整合素 αvβ3 和 αvβ5。 兩種整合素在許多癌癥中過度表達(dá),例如非小細(xì)胞肺癌和黑色素瘤以及生長的血管。
RGD-4C binds preferentially to integrins αvβ3 and αvβ5. Both integrins are overexpressed in many cancers such as non-small cell lung cancer and melanoma and growing vessels.
RGD-4C is a cell-adhesive peptide that binds αvβ3 and αvβ5 integrins; these integrins are overexpressed in many cancers and growing vessels, so RGD-4C is often attached to viral treatments to better deliver or target the treatment to cancerous tissues.
中文名稱:RGD-4C
英文名:RGD-4C
CAS號(hào):332179-76-7
單字母:ACCENLADTYRGPCF
三字母:Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly(Disulfide Bridge: Cys2-Cys10, Cys4-Cys8)
氨基酸個(gè)數(shù):15
分子式:C69H103N19O23S3
平均分子量:1662.86462
***分子量:1661.6635225
等電點(diǎn)(PI):9
pH=7.0時(shí)的凈電荷數(shù):2.86
酸性基團(tuán)個(gè)數(shù):-1.18
堿性基團(tuán)個(gè)數(shù):親水
平均親水性:-0.22307692307692
來源:Synthetic
純度:95%、98%
鹽體系:可選TFA、HAc、HCl或其它
儲(chǔ)存條件:-20±5 °C
外觀與性狀:白色粉末狀固體
DOTA-RGD-4C,DOTA偶聯(lián)RGD-4C多肽
相關(guān)試劑列表:
DOTA-SP94 DOTA偶聯(lián)肝癌特異靶向肽SP94
DOTA-TH DOTA偶聯(lián)PH響應(yīng)性細(xì)胞穿膜肽TH
DOTA-M918 DOTA偶聯(lián)細(xì)胞穿膜肽M918
DOTA-YTA2 DOTA偶聯(lián)細(xì)胞穿膜肽YTA2
DOTA-YTA4 DOTA偶聯(lián)細(xì)胞穿膜肽YTA4
DOTA-Pep-1 DOTA偶聯(lián)細(xì)胞穿膜肽Pep-1
DOTA-TAT(48-60) DOTA偶聯(lián)細(xì)胞穿膜肽TAT(48-60)
DOTA-MAP DOTA偶聯(lián)細(xì)胞穿膜肽MAP
DOTA-CADY DOTA偶聯(lián)細(xì)胞穿膜肽CADY
DOTA-pVEC DOTA偶聯(lián)細(xì)胞穿膜肽pVEC
DOTA-MPG DOTA偶聯(lián)細(xì)胞穿膜肽MPG
DOTA-TAT(48-60) DOTA偶聯(lián)細(xì)胞穿膜肽 TAT
DOTA-TAT2-4 DOTA偶聯(lián)細(xì)胞穿膜肽TAT2-4